NURIX THERAPEUTICS, INC. Revenue Breakdown
No Revenue Breakdown for NRIX on this site yet.
- 2025-11-30: Others Not split by product in the filing$83.98M100.00%; Total revenue $83.98M.
- 2024-11-30: Others Not split by product in the filing$54.55M100.00%; Total revenue $54.55M.
- 2023-11-30: Others Not split by product in the filing$76.99M100.00%; Total revenue $76.99M.
- 2022-11-30: Others Not split by product in the filing$38.63M100.00%; Total revenue $38.63M.
Source checked: the stored Revenue Breakdown page for NRIX.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2025-11-30 | Not split by product in the filing $83.98M 100.00% | $83.98M |
| 2024-11-30 | Not split by product in the filing $54.55M 100.00% | $54.55M |
| 2023-11-30 | Not split by product in the filing $76.99M 100.00% | $76.99M |
| 2022-11-30 | Not split by product in the filing $38.63M 100.00% | $38.63M |
| 2021-11-30 | Not split by product in the filing $29.75M 100.00% | $29.75M |
| 2020-11-30 | Not split by product in the filing $17.82M 100.00% | $17.82M |
| 2019-11-30 | Not split by product in the filing $31.11M 100.00% | $31.11M |
Each quarter (3 month)
| Quarter end | Others | Total revenue |
|---|---|---|
| 2026-05-31 | Not split by product $9.04M 100.00% | $9.04M |
| 2026-02-28 | Not split by product $6.25M 100.00% | $6.25M |
| 2025-11-30 | Not split by product $13.58M 100.00% | $13.58M |
| 2025-08-31 | Not split by product $7.89M 100.00% | $7.89M |
| 2025-05-31 | Not split by product $44.06M 100.00% | $44.06M |
| 2025-02-28 | Not split by product $18.45M 100.00% | $18.45M |
| 2024-11-30 | Not split by product $13.28M 100.00% | $13.28M |
| 2024-08-31 | Not split by product $12.59M 100.00% | $12.59M |
| 2024-05-31 | Not split by product $12.09M 100.00% | $12.09M |
| 2024-02-29 | Not split by product $16.59M 100.00% | $16.59M |
| 2023-11-30 | Not split by product $15.16M 100.00% | $15.16M |
| 2023-08-31 | Not split by product $18.47M 100.00% | $18.47M |
| 2023-05-31 | Not split by product $30.68M 100.00% | $30.68M |
| 2023-02-28 | Not split by product $12.69M 100.00% | $12.69M |
| 2022-11-30 | Not split by product $6.78M 100.00% | $6.78M |
| 2022-08-31 | Not split by product $10.79M 100.00% | $10.79M |
| 2022-05-31 | Not split by product $11.43M 100.00% | $11.43M |
| 2022-02-28 | Not split by product $9.62M 100.00% | $9.62M |
| 2021-11-30 | Not split by product $7.40M 100.00% | $7.40M |
| 2021-08-31 | Not split by product $10.25M 100.00% | $10.25M |
| 2021-05-31 | Not split by product $7.09M 100.00% | $7.09M |
| 2021-02-28 | Not split by product $5.01M 100.00% | $5.01M |
| 2020-11-30 | Not split by product $6.69M 100.00% | $6.69M |
| 2020-08-31 | Not split by product $4.08M 100.00% | $4.08M |
| 2020-05-31 | Not split by product $4.18M 100.00% | $4.18M |
| 2020-02-29 | Not split by product $2.86M 100.00% | $2.86M |
| 2019-11-30 | Not split by product $1.86M 100.00% | $1.86M |
| 2019-08-31 | Not split by product $10.58M 100.00% | $10.58M |
| 2019-05-31 | Not split by product $9.44M 100.00% | $9.44M |
| 2019-02-28 | Not split by product $9.23M 100.00% | $9.23M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |